Multimodal treatments for advanced prostate cancer

In 2018, an estimated 164,000 men in the United States will be newly diagnosed with prostate cancer. Among these men, at least 10% will present with locally or regionally advanced disease. In contrast to men with clinically localized prostate cancer, where 5-year relative survival rates approach 100%, men with locally advanced (T3-T4 N0 M0) or regionally advanced (T3-T4 N1 M0) prostate cancer are at high risk of death from their disease [1]